Navigation Links
Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
Date:10/5/2009

nphier, Sangamo's President and CEO. "Sigma-Aldrich has been aggressively developing, marketing and distributing ZFP-based products through their CompoZr website, and we anticipate the same success in these expanded markets of cell line engineering and transgenic animal products. Sangamo's business model enables us to access non-dilutive funding for our core ZFP Therapeutic(TM) programs by monetizing the industrial applications of our ZFP technology with a focused and committed partner. Sigma-Aldrich has proven to be just that."

For more information on Sigma-Aldrich's CompoZr ZFN technology platform, visit http://www.compozrzfn.com or contact a sales representative at zfn@sial.com.

Terms of the License Agreement Amendment

The expanded agreement provides Sigma-Aldrich with exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals for livestock, companion animals and therapeutic protein production. Sangamo retained all rights to ZFP-modified transgenic animals for discovery of novel therapeutics and the right to use ZFPs as therapeutic products. Under this agreement, Sigma-Aldrich will make initial payments of $20.0 million to Sangamo, consisting of an upfront license payment of $15.0 million and $5.0 million through the purchase of 636,133 shares of Sangamo common stock at market price. Market price is determined by the average closing price of Sangamo stock over the past 30 trading days, or $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 million to $10.0 million, up to a tota
'/>"/>

SOURCE Sigma-Aldrich Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
2. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
3. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
4. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
5. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
6. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
8. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
9. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
10. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... N.Y., Dec. 15 On January 20th, ... Society for Medical Publication Professionals (ISMPP) will be ... London, UK. More than 100 attendees are expected ... for publication professionals, editors, publishers, medical writers and ... medical publications and the impact of guidelines and ...
(Date:12/15/2009)... of several innovative new programs to aid cash-strapped entrepreneurs ... climate. The first is aimed at entrepreneurs and ... a period of 6, 12, 18, or 24 months ... The second is aimed at more established businesses and ... 12 month period at discounted rates, and even the ...
(Date:12/14/2009)... Dec. 14 Dyadic International, Inc. (Pink ... extended its collaboration with The Scripps Research Institute ... to re-annotate the genome of Dyadic,s patented and ... a continuation of the successful relationship between the ... Dyadic engaged Scripps to annotate the C1 genome ...
(Date:12/14/2009)... 14 Boston Scientific Corporation (NYSE: ... offering of $2 billion aggregate principal amount of its ... The public offering consists of $850 million of 4.50 ... percent notes due January 2020 and $300 million of ... plans to use the net proceeds for general corporate ...
Breaking Biology Technology:Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3
... Key milestones, - Strong R&D investments, especially in EHT Dx21 and ... - Recruitment of 311 samples achieved for EHT Dx21, ... - Expansion of the strategic collaboration with Allergan and extension, ... Appointment of a new Management Board, - New positioning of Genomic ...
... March 3 NeoGenomics, Inc. (OTC Bulletin Board: ... its fourth quarter and full year 2008 financial results on ... conference call to discuss their Q4 and full year 2008 ... Interested investors should dial (877) 407-8033 (domestic) and (201) 689-8033 ...
... Leverage Respective Technology and Market Experience to Support ... Sparta Systems, Inc., the leading provider of ... the appointment of two software and life sciences ... Diane Carlson, vice president of marketing communications, and ...
Other Biology Technology:ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11NeoGenomics Schedules its Q4 and Full Year 2008 Earnings Release for March 5, 2009 2Sparta Systems Bolsters Executive Leadership Team with Strategic Additions 2Sparta Systems Bolsters Executive Leadership Team with Strategic Additions 3
(Date:12/15/2009)... WI, December 15, 2009 Economics, environmental impacts, ... factors that influence the overall success of an ... on the system, forcing individuals and social groups ... order to survive. , Experiential learning theory ... result of firsthand experiences. Such lessons are especially ...
(Date:12/15/2009)... American researchers found the fossil remains of a whale, 4.5 ... for the first time, the results of the decay and ... cetacean, possibly a baleen whale from the Mysticeti group. , ... remains of a whale from the Lower Pliocene (five million ... is the first time that the results of the processes ...
(Date:12/15/2009)... HERNDON, Va., Dec. 15 The PTR Group, ... today announced that it has agreed to sponsor three ... US FIRST Robotics Competition ( http://usfirst.org ). ... high school teams in three different states. The ... in Rockwall, TX, and James Madison HS in Vienna, ...
Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 13440 1ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 13440 2LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 53923 1LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 53923 2Matrixx Initiatives Inc Sets Time for Discussion of First Quarter Fiscal 2010 Financial Results 53918 1Matrixx Initiatives Inc Sets Time for Discussion of First Quarter Fiscal 2010 Financial Results 53918 2
... in the body, a virus such as HIV invades body ... membrane. Once inside the cell, the invading microbe's genetic material ... produce more copies of the virus, which then spill out ... assumed that once a virus begins fusing with a cell's ...
... in the impact of malaria is in prospect with a ... next year. Success in the trial would open the way ... debilitating and often fatal disease - over 500,000,000 people. ... is collaborating with the Papua New Guinea Institute of Medical ...
... San Francisco VA Medical Center (SFVAMC) and the University ... associated with lymphocytic bronchitis, which is thought to lead ... long-term failure of transplanted lungs. , The researchers hope ... and more accurate standard test for chronic lung rejection, ...
Other Biology News:Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Old drug, new tricks: Prospects for slashing the impact of malaria 2Researchers identify genes associated with lung transplant rejection 2
... Safe photographic filter (S37100, Photographic Filters ... is ideal for black-and-white photography of ... DNA gel stain, the safer ethidium ... Safe photographic filter is identical to ...
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
LAL Chromogenic Endpoint assay...
Biology Products: